ESR1 and breast cancer: For that reason, the suppression of estrogen synthesis with aromatase inhibitors, or the use of ERα antagonists, either selective ER modulators (SERMs) or selective ER downregulators (SERDs), have remained the pillars of ERα+ BC treatment for several decades [9].